Clinical Trial Update: Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy Subjects [Phase 1, Phase 2]

View source ↗

Summary

The document describes a combined Phase 1/2 safety and efficacy trial for NGGT001 in Bietti Crystalline Corneoretinal Dystrophy, currently listed as active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bietti Crystalline Corneoretinal Dystrophy

Drugs mentioned

• NGGT001

Snippet

Sponsor: NGGT (Suzhou) Biotechnology Co., Ltd. | Conditions: Bietti Crystalline Corneoretinal Dystrophy | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING